Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Study Comparing i.v. Busulfan (Busilvex®) Plus Fludarabine (BuFlu) Versus Busilvex® Plus Cyclophosphamide (BuCy2) as Conditioning Regimens Prior AlloHSCT in Patients (Age >= 40 and =<65 Years) With AML in Complete Remission.

NCT01191957 is registered in ClinicalTrials.gov with Gruppo Italiano Trapianto di Midollo Osseo as lead sponsor.

NCT NCT01191957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01191957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Study Comparing i.v. Busulfan (Busilvex®) Plus Fludarabine (BuFlu) Versus Busilvex® Plus Cyclophosphamide (BuCy2) as Conditioning Regimens Prior AlloHSCT in Patients (Age >= 40 and =<65 Years) With AML in Complete Remission.
Lead sponsor
Gruppo Italiano Trapianto di Midollo Osseo
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2008
Completion date
October 31, 2014
Enrollment
252 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)